Cefaclor is an antibiotic used for managing bacterial infections across multiple systems.

Cefaclor Aristo is commonly used in conditions characterized by periods of heightened symptoms associated with inflammatory or irritative states. Specifically, it is relevant for managing symptomatic infections of the lower and upper respiratory tracts (such as pneumonia and tonsillitis), the middle ear (otitis media), the urinary tract (including cystitis and pyelonephritis), and specific skin and soft tissue infections.

In clinical scenarios where symptoms interfere with daily functioning, such as intense earache, sore throat, or painful urination, the medication is applied to address these acute or disruptive symptom patterns. The use of this medication helps support the patient during difficult episodes, which may assist with easing the symptom burden related to localized discomfort. This applies across various patient groups, including adults, children (infants from 1 month), and older adults.

---

Quick Fact: Relief for Localized Discomfort Cefaclor Aristo is commonly used to help with symptoms related to physical discomfort in conditions like otitis media and cystitis, supporting the patient during phases when pain and inflammation become more noticeable.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who Can and Cannot Use Cefaclor Aristo

Cefaclor Aristo is authorized for use in adults, adolescents, and pediatric patients who are one month of age or older. Eligibility is defined by formal regulatory rules regarding absolute prohibitions and populations requiring special precautions.

Who Must Not Use This Medicine (Contraindications):

Use of Cefaclor Aristo is strictly contraindicated for any patient with a known hypersensitivity or allergy to cefaclor or to any other antibiotic in the cephalosporin class. A history of a severe allergic reaction to penicillin is also considered a high-risk contraindication due to potential cross-allergenicity.

Age-Based Restrictions:

Safety and efficacy have not been established for use in infants less than one month of age, rendering this population ineligible.

Populations Requiring Conditional Use:

The medicine must be administered with caution in patients with markedly impaired renal function, a history of gastrointestinal disease (particularly colitis), or hepatic disease. For pregnant women (FDA Pregnancy Category B) and breastfeeding mothers, use is conditional and should occur only if clearly needed, based on official documentation.

Interactions with other medicines and products

The interaction profile of Cefaclor Aristo is formally defined by its effects on renal clearance, gastrointestinal absorption, and pharmacodynamic interactions with other agents, as stated in government regulatory documents.

Exposure and Clearance Alterations

The drug Probenecid causes a pharmacokinetic interaction by inhibiting the renal tubular secretion of Cefaclor, which results in increased and prolonged serum concentrations of the antibiotic. This alteration in clearance is a documented interaction.

Absorption Timing Requirements

Antacids that contain aluminum or magnesium hydroxides can diminish the overall extent of Cefaclor absorption. For the extended-release tablet formulation, regulatory labels state that such antacids must be administered one hour before or one hour after the Cefaclor dose to manage this interaction. Food consumption affects the rate, but not the total amount absorbed, by reducing the peak concentration (Cmax) and delaying its appearance.

Pharmacodynamic Interactions

Co-administration with oral anticoagulants, such as Warfarin, has been associated with reports of increased prothrombin time and risk of bleeding. Furthermore, there is a documented potential for an additive nephrotoxic effect when Cefaclor is used with other nephrotoxic drugs, including aminoglycosides or certain diuretics.

Laboratory Interference

Cefaclor may cause a false-positive reaction for glucose in the urine when specific copper-sulfate reduction tests (e.g., Clinitest) are used, a procedural constraint noted in the official profile.

Cefaclor Aristo functions as a beta-lactam antibiotic, targeting the essential structural integrity of susceptible bacterial cells.

Its core mechanism involves the inhibition of cell wall synthesis. Cefaclor achieves this by acting as an irreversible inhibitor of specific enzymes located on the inner membrane of the bacterial cell wall, known as Penicillin-Binding Proteins (PBPs). These PBPs are transpeptidases critical for cross-linking peptidoglycan units, the final stage in assembling the cell wall's rigid structure.

Binding of Cefaclor to the active site of PBPs prevents the formation of these peptidoglycan cross-links. This disruption leads to a compromised, structurally unsound cell wall. The ensuing mechanistic cascade involves the activation of bacterial cell wall autolytic enzymes (autolysins). The combination of arrested synthesis and uninhibited lytic activity leads to osmotic instability and ultimately, the disintegration of the bacterial cell structure.

How to Use Cefaclor Aristo: Official Administration Guidelines

Cefaclor Aristo is administered exclusively via the oral route, with dosing and administration conditions defined for each specific formulation. The medication is available as immediate-release capsules or suspensions and as extended-release tablets, each carrying distinct usage instructions.

---

General Dosing and Frequency

The standard adult dosage for Immediate-Release (IR) Cefaclor (capsules/suspension) is typically 250 mg every 8 hours, administered in divided doses three times daily. For severe infections, the dose may be increased to 500 mg every 8 hours, up to a maximum total daily dose of 4 g. The total daily dosage may alternatively be divided and administered every 12 hours for specific conditions. Extended-Release (ER) Tablets are generally taken every 12 hours.

---

Administration Conditions and Handling

Instruction Type	Immediate-Release (Capsules/Suspension)	Extended-Release (Tablets)
Relation to Food	Can be taken with or without food (absorption is unchanged).	Must be taken with food (absorption is enhanced by meals).
Handling Restriction	No specific handling restriction on capsules. Suspension must be reconstituted with water and shaken well before each use.	Tablets must be swallowed whole; they must not be cut, crushed, or chewed to maintain the controlled release mechanism.

---

Duration and Special Populations

Treatment duration should be maintained for a minimum of 48 to 72 hours after the patient becomes asymptomatic. Specifically, therapy for infections caused by beta-haemolytic streptococci must be continued for a minimum of 10 days. Pediatric dosage (1 month) is determined by body weight, typically 20 mg/kg/day in divided doses. Dosage adjustments are not typically required for older adults or in patients with moderate to severe renal impairment.

Research evidence / Overview of studies for Cefaclor Aristo

Evidence for Acute Respiratory and Ear Infections

Research has explored the use of Cefaclor Aristo for conditions characterized by episodic or acute changes in the lower and upper respiratory tracts, as well as the middle ear. The evidence base relies on short-term Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews that have explored its use for conditions like otitis media and acute flare-ups of chronic bronchitis.

Studies conducted during periods of increased symptom activity generally focused on two primary outcomes: assessing clinical response (how symptoms evolved in the observed populations) and measuring bacteriological outcomes (pathogen presence or absence following treatment). For acute otitis media, trials were structured to assess clinical failure rates (lack of symptom resolution or worsening of the condition) in the pediatric population. Systematic Reviews indicate that findings were mixed in some comparative reviews, with some studies describing patterns where clinical failure rates were observed to vary, while other antibiotics were also observed.

---

Evidence for Urinary Tract and Skin Infections

Research has examined Cefaclor Aristo for conditions associated with acute or disruptive episodes in the urinary tract (UTI) and for uncomplicated skin and soft tissue infections (SSTI). The evidence structure is built on comparative clinical studies that were used in research examining these specific uses.

These studies explored outcomes related to physical discomfort and physiological strain, primarily focusing on whether outcomes related to physiological strain were measured, which is typically measured as the percentage of patients reporting a favorable clinical status at the end of treatment. For SSTI, this research describes what has been observed so far in cohorts of adults and children with uncomplicated infections caused by susceptible bacteria. Studies reported how symptoms evolved in the observed populations following treatment courses, with outcomes often assessed within a short-term window.

---

Research Focusing on Special Populations

Studies have explored the use of Cefaclor Aristo across various patient groups, with particular attention paid to the pediatric population for indications like otitis media and pharyngitis. The research was evaluated in children and adolescents, with some analyses further stratifying by age to look for different patterns in younger children. Research also includes studies evaluating the drug in adults and older adolescents for lower respiratory tract conditions. Research has explored cohorts that included individuals with underlying chronic conditions, such as chronic bronchitis, where the drug was evaluated in studies focusing on episodes where symptoms become more noticeable.

---

Research Gaps and Areas of Uncertainty

Research highlights areas where the evidence is limited or where more research is needed. Specifically, the data remain insufficient for treating complicated or severe infections of the skin or urinary tract, as the existing trials primarily focused on uncomplicated cases.

Comparative evidence is lacking for certain outcomes, and findings were mixed when Cefaclor was studied alongside other treatments, leading to varied patterns being observed. Furthermore, the results apply only to the populations studied and do not provide insight into the drug's activity against new or resistant bacterial strains that were not prevalent when the pivotal studies were conducted. These gaps mean that the research provides context but does not determine whether an individual will respond similarly to the group patterns observed in the studies.

Key Studies & References Label: CEFACLOR suspension - DailyMed - NIH (US Regulatory/Indications Document)

Common questions about Cefaclor Aristo (FAQ)

Q: Is Cefaclor Aristo the same as Cefaclor?

Cefaclor is the active ingredient that targets the bacterial infection. Cefaclor Aristo is the brand name used by the manufacturer Aristo Pharma for its specific formulation of the medication, according to official product information.

Q: What kind of bacteria does Cefaclor Aristo target?

Regulatory documents indicate that Cefaclor is active against many types of susceptible bacteria. This includes several common Gram-positive bacteria, such as those that cause strep throat, and certain Gram-negative bacteria, such as those that can cause infections like E. coli.

Q: Is Cefaclor Aristo a penicillin-type drug?

No, Cefaclor is classified as a cephalosporin antibiotic, which is distinct from the penicillin group. However, official warnings note that cross-hypersensitivity (a shared allergic reaction) can occur between cephalosporins and penicillins. Regulatory information notes this is a key factor addressed by healthcare professionals.

Q: How long does it usually take for Cefaclor Aristo to start working?

According to official clinical pharmacology data, Cefaclor typically reaches its peak concentration in the bloodstream within 30 to 90 minutes after an immediate-release dose. While the drug’s activity begins after absorption, clinical expectations suggest that a patient's symptoms may begin to show improvement within the first few days of starting treatment.

Q: Is feeling tired a reported side effect of Cefaclor Aristo?

Drowsiness, known medically as somnolence, is reported in official side-effect reports for some formulations of Cefaclor. This is typically noted as an uncommon or rare side effect, meaning it is not experienced by most patients.

Q: What happens if I forget to take a dose?

Official product information contains specific guidelines regarding missed doses. These guidelines describe the circumstances under which a patient should take the missed dose and when it may be appropriate to skip it, in order to maintain a consistent treatment schedule.

Q: Are there any specific foods to avoid while taking Cefaclor Aristo?

Official sources do not describe specific foods that require avoidance. For the Extended-Release tablets, however, official product information describes administration conditions that include taking the tablets with food to enhance absorption.

Q: Can Cefaclor Aristo affect birth control pills?

Official product information for Cefaclor notes that antibiotics in this class may reduce the effects of certain hormone-based medications, specifically conjugated estrogens found in some oral contraceptives. This could potentially increase the risk of pregnancy or cause breakthrough bleeding.

Q: Is it okay to drink alcohol while taking Cefaclor Aristo?

The official Cefaclor label typically does not state a direct, severe interaction with alcohol. However, alcohol consumption may worsen potential drug side effects, such as dizziness or stomach upset. Official documents focus on the drug’s potential side effects, which could be relevant when considering alcohol consumption.

Q: What should I do if I develop a rash after starting Cefaclor Aristo?

The official label describes that, upon the appearance of allergic reaction signs like a rash, discontinuation of the medication is warranted. Regulatory documents emphasize that severe reactions, such as anaphylaxis (a severe allergic reaction), are serious events.

Q: Can Cefaclor Aristo cause yeast infections?

While not a common side effect itself, regulatory documents mention that using antibacterial agents can potentially lead to superinfections—infections caused by non-susceptible organisms. This is a possibility because antibiotics can disrupt the natural balance of bacteria in the body.

Q: Is Cefaclor Aristo linked to anxiety or mood changes?

According to the official side effects reports, anxiety, insomnia, and nervousness have been noted as uncommon or rare neurological side effects for some formulations. These are formally listed under the category of psychiatric disorders.

Q: Can Cefaclor Aristo interact with diabetes medication?

Regulatory information notes that Cefaclor can cause a false-positive result for glucose in the urine when using specific laboratory tests that rely on copper-sulfate reduction (like Clinitest). This is a known procedural constraint that may affect how diabetes is monitored.

Q: Does Cefaclor Aristo contain lactose?

Yes, the inactive ingredients listed in the official labeling for certain formulations, such as the capsules and oral suspension powder, include lactose monohydrate.

Q: Is Cefaclor Aristo known to interact with herbal supplements?

Official product information notes the importance of disclosing all products being used, which includes prescriptions, non-prescriptions, vitamins, and herbal or nutritional supplements, to allow for a full review of potential interactions.

Q: What happens if I stop taking Cefaclor Aristo early?

Official patient information states that if treatment is stopped too soon, the bacterial infection may not be completely cured. Furthermore, there is a risk that the remaining bacteria could become resistant to the antibiotic, making future infections harder to treat.

Q: Can I drive or operate machinery while taking Cefaclor Aristo?

Because some patients have reported side effects like dizziness or somnolence (drowsiness), the safety profile indicates caution is warranted. Regulatory warnings describe that potential effects, such as dizziness, may require individuals to consider their fitness for activities like driving.

Q: What is the purpose of the excipients in Cefaclor Aristo tablets?

Official documents describe excipients (inactive ingredients) as substances that serve a technical role in the final drug product. Their purpose is to aid in the formulation, stability, and proper release of the active ingredient, such as maintaining the correct structure of a tablet or capsule.

Q: Can Cefaclor Aristo affect liver function test results?

The official safety profile lists transient elevations in liver enzymes as an uncommon adverse reaction. This documented enzyme elevation is what is measured by these tests, serving as the factual basis for potential effects on test results.

Q: Is there a generic version of Cefaclor Aristo available?

Cefaclor is the active ingredient and is widely available from many manufacturers. While Cefaclor Aristo is a brand-name product, the active ingredient Cefaclor is available in many other generic and branded forms.

Q: Do studies mention antibiotic resistance concerns with Cefaclor Aristo?

Research documents caution that the existing study results apply only to the populations and bacteria prevalent at the time of the trials. They note that the data cannot provide insight into the drug's activity against new or resistant bacterial strains that were not examined in the pivotal studies.

Q: What is the maximum amount of time Cefaclor Aristo is typically prescribed for?

Official administration guidelines focus on the minimum duration of treatment, such as 48 to 72 hours after becoming asymptomatic. Regulatory documents do not specify a universal maximum duration, as the total course length is based on the specific type and severity of the patient's infection.

Q: Is Cefaclor Aristo considered a common antibiotic?

Cefaclor is described in official sources as a widely recognized semisynthetic antibiotic within the second-generation cephalosporin class. It is an established medicine used globally for managing a range of bacterial infections.

Q: How does Cefaclor Aristo compare to other cephalosporins?

Cefaclor is formally categorized as a second-generation cephalosporin. This classification means it has a defined range of activity, balancing effectiveness against certain Gram-positive bacteria while showing increased activity against certain Gram-negative bacteria compared to the older, first-generation cephalosporins.

Q: Are there different strengths available for Cefaclor Aristo?

Yes. The official dosing guidelines reference multiple formulations and concentrations, including capsules in 250 mg and 500 mg strengths, as well as a suspension form. The specific strength prescribed depends on the infection being treated.

Q: Is Cefaclor Aristo described as highly effective in regulatory documents?

Regulatory research summaries describe the drug's use in various studies for conditions like respiratory and ear infections. These documents focus on outcomes like clinical and bacteriological response and note that findings were mixed in some comparative reviews where other agents were also evaluated.

Storage and Disposal Requirements

Cefaclor storage depends on its form to maintain stability. The capsules and dry powder for suspension must be stored at Controlled Room Temperature (between 15°C and 30°C or 59°F and 86°F), protected from light and moisture, and kept in a tight, light-resistant container.

Stability of Oral Suspension

Form	Temperature Requirement	Stability Period
Reconstituted Suspension	Refrigerated (2°C to 8°C)	14 days maximum

The reconstituted suspension must not be frozen. All forms must be stored out of the sight and reach of children.

Disposal

Unused or expired Cefaclor should be disposed of via a drug take-back program. If a program is unavailable, the medication should be mixed with an undesirable substance (e.g., used coffee grounds) and placed into a sealed container before discarding in household trash, as outlined by regulatory guidelines.